CSIMarket Company Name, Ticker, Customers, else..
 
Adverum Biotechnologies Inc   (NASDAQ: ADVM)
 
Price: $4.3600 $0.10 2.347%
Day's High: $4.3785 Week Perf: 4.81 %
Day's Low: $ 4.23 30 Day Perf: 1.87 %
Volume (M): 1,023,000 52 Wk High: $ 5.75
Volume (M$): $ 4,460 52 Wk Avg: $4.18
Open: $4.24 52 Wk Low: $2.87



 Market Capitalization (Millions $) 102
 Shares Outstanding (Millions) 23
 Employees 121
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -204
 Cash Flow (TTM) (Millions $) -52
 Capital Exp. (TTM) (Millions $) 1

Business Description


Adverum Biotechnologies Inc is a clinical-stage gene therapy company that focuses on developing novel treatments to treat serious ocular diseases. The company's primary objective is to use gene therapy to provide long-term solutions for patients suffering from conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Adverum aims to deliver its therapies using its proprietary vector platform, which is designed to efficiently and effectively deliver therapeutic genes to the eye. The company is actively engaged in clinical trials and continues to advance its pipeline of potential gene therapies to address unmet medical needs in the field of ophthalmology.


   Company Address: 100 Cardinal Way Redwood City 94063 CA
   Company Phone Number: 656-9323   Stock Exchange / Ticker: NASDAQ ADVM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        1.11% 
ATRA        6.09% 
BIIB        1.07% 
EXEL        8.37% 
HALO        4.59% 
IMCR   -1.34%    
• View Complete Report
   



Clinical Study

Adverum Biotechnologies Advances Towards Pivotal Phase 3 Trial Completion for Ixo-vec in Wet AMD Treatment

Published Mon, Sep 22 2025 12:30 PM UTC

In an important development for ocular gene therapy, Adverum Biotechnologies, Inc. (Nasdaq: ADVM) has announced the imminent completion of patient screening for its pivotal Phase 3 ARTEMIS trial evaluating Ixo-vec, a groundbreaking therapy for wet age-related macular degeneration (wet AMD). This announcement, made on September 22, 2025, highlights the company s commitment to...
Clinical Study

Adverums ARTEMIS Phase 3 Study Pioneering a Future in Gene Therapy for Wet AMD,

Published Thu, Jun 19 2025 12:57 PM UTC

Innovative Advances in Gene Therapy: Adverum Biotechnologies Initiates Pivotal ARTEMIS Phase 3 Study for Wet AMD Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a pioneer in the field of gene therapy, has taken a significant step forward in the management of wet age-related macular degeneration (AMD) with the initiation of its ARTEMIS Phase 3 study. This groundbreaking trial a...
Announcement

Pomerantz Law Firm Launches Investigation into Adverum Biotechnologies Implications for Investors Amidst Revenue Conc...

Published Fri, May 9 2025 5:05 PM UTC

In a significant development for investors, Pomerantz LLP has announced its investigation into potential claims on behalf of shareholders of Adverum Biotechnologies, Inc. (NASDAQ: ADVM). The announcement, made on May 9, 2025, seeks to address concerns regarding the company s financial health and operational performance, particularly in light of its recent revenue challenges....
Shares

Adverum Biotechnologies Bets on Talent Acquisition with Strategic Inducement Grants Amid Nasdaq Compliance,

Published Fri, May 2 2025 8:01 PM UTC

Adverum Biotechnologies Moves to Attract Talent with Inducement Stock Awards Under Nasdaq RegulationsIn a strategic move to bolster its workforce, Adverum Biotechnologies, Inc. (Nasdaq: ADVM) has announced the granting of inducement awards to seven new employees. The Compensation Committee of Adverum’s Board of Directors has approved these grants, which include nonqualifi...
Announcement

Adverum Biotechnologies Faces Investor Concerns Amidst Stagnant Performance in Booming Biotech Sector,

Published Fri, Apr 25 2025 8:42 PM UTC

Adverum Biotechnologies, Inc. Under Investor Scrutiny Amidst Comparatively Stagnant Performance Pomerantz Law Firm, a highly respected and longstanding authority in securities litigation, has recently announced an investigation on behalf of investors in Adverum Biotechnologies, Inc. This investigation serves to delve into potential claims concerning the company, particularly...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.58
Working Capital Ratio 0.65
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -8.69 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 1.11 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,689,190
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.